FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
- 1	hours nor roomanas:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_													
1. Name and Address of Reporting Person* Makela Jan						2. Issuer Name and Ticker or Trading Symbol GE HealthCare Technologies Inc. [GEHC]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (a) to title Other (appliful)				
(Last) (First) (Middle) 500 W. MONROE STREET						Date of 13/2		est Trans	saction (N	/lonth	/Day/Year)		X Officer (give title Other (special below) CEO, Imaging					
					4.1	If Ame	endme	nt, Date o	of Origina	ıl File	d (Month/Da		6. Individual or Joint/Group Filing (Check Applicable					
(Street)											- 1	Line) X Form filed by One Reporting Person						
CHICAC	ICAGO IL 60661				_								Form filed by More than One Reporting Person					
(City) (State) (Zip)				R	Rule 10b5-1(c) Transaction Indication													
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	le I - No	n-Deri	vativ	e Se	curit	ies Ac	quired	, Dis	sposed o	f, or Ber	neficial	ly Owned				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				ey/Year) Exe		2A. Deemed Execution Date, f any Month/Day/Year)		Transaction Disposed (es Acquired (A) or Of (D) (Instr. 3, 4 and 5)		Securition Benefici Owned I	5. Amount of Securities Beneficially Owned Following		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	Code V Amount		(A) or (D)	Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common	Stock, par	value \$0.01 per	share	05/13	3/2024	2024		М		20,227	Α	\$63.5	1 83	83,575		D		
Common Stock, par value \$0.01 per share			05/13	05/13/2024				S		20,227	D	\$81.57	63	63,348		D		
Common Stock, par value \$0.01 per share			05/15	5/2024				M		8,388	A	\$63.5	1 71	71,736		D		
Common Stock, par value \$0.01 per share 05/15/2				5/2024	2024			M		25,472	A	\$75.3	97	97,208		D		
Common Stock, par value \$0.01 per share 05/15/			5/2024	2024			M		33,095	A	\$76.3	7 130	130,303		D			
Common Stock, par value \$0.01 per share 05/15/2			5/2024	2024		S		66,955 D \$		\$81.54	(2) 63	63,348		D				
		•	Table II								osed of, convertil			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	n Date,	4. Transa	ansaction of December 1 of December 1 of December 2 of Dec		umber vative urities uired	•	xerci on Da	sable and	7. Title and of Securiti Underlying Derivative (Instr. 3 an	d Amount es g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	s B Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (right to buy)	\$63.51	05/13/2024			M			20,227	(3)		03/02/2030	Common Stock, par value \$0.01 per share	20,227	\$0	8,388	:	D	
Employee Stock Option (right to buy)	\$63.51	05/15/2024			M			8,388	(3)		03/02/2030	Common Stock, par value \$0.01 per share	8,388	\$0	0		D	
Employee Stock Option (right to buy)	\$75.3	05/15/2024			M			25,472	(4)		03/01/2033	Common Stock, par value \$0.01 per share	25,472	\$0	0		D	
Employee Stock Option (right to buy)	\$76.37	05/15/2024			M			33,095	(5)		07/01/2031	Common Stock, par value \$0.01 per share	33,095	\$0	33,096	6	D	

Explanation of Responses:

- 1. The price reported represents the weighted average price of shares sold. These shares were sold in multiple transactions at prices ranging from \$81.50 to \$81.84, inclusive. The Reporting Person undertakes to provide GE HealthCare Technologies Inc. ("GE HealthCare"), any security holder of GE HealthCare, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
- 2. The price reported represents the weighted average price of shares sold. These shares were sold in multiple transactions at prices ranging from \$81.50 to \$81.68, inclusive. The Reporting Person undertakes to provide GE HealthCare, any security holder of GE HealthCare, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
- 3. Award of an employee stock option with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by General Electric Company ("GE") as a result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare by GE to holders of GE common stock on a pro rata basis (the "Spin-Off"), of which 100% became exercisable on March 2, 2023.
- 4. Award of an employee stock option with respect to GE HealthCare common stock, of which 100% became exercisable on March 1, 2024.
- 5. Award of an employee stock option with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by GE as a result of the Spin-Off, of which 50% became exercisable on July 1, 2023 and 50% will become exercisable on July 1, 2024.

Remarks:

/s/ Frank R. Jimenez, General Counsel and Corporate Secretary, as attorney-in-fact

05/15/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).